



Research Article

Bioavailability Study of Maxicura Capsules Versus Micronized Curcumin Capsules as A Single Oral Dose in Fasted Healthy Adult Human Subjects

Manish Rachchh*, Rina Gokani, Hetal Patel, Jainik Khamar, Apurva Patel

Accuprec Research Labs Pvt. Ltd., Ahmedabad, Gujarat, India.

*Corresponding author: Dr. Manish Rachchh, Accuprec Research Labs Pvt. Ltd., Ahmedabad, Gujarat, India.

Citation: Rachchh M, Gokani R, Patel H, Khamar J, Patel A (2023) Bioavailability Study of Maxicura Capsules Versus Micronized Curcumin Capsules as A Single Oral Dose in Fasted Healthy Adult Human Subjects. Curr Res Cmpl Alt Med 7: 191. DOI: 10.29011/2577-2201.100091

Received Date: 12 July 2023; **Accepted Date:** 24 July 2023; **Published Date:** 27 July 2023

Abstract

Aim: The purpose of this study is to evaluate and compare the amount of free Curcumin in the human blood plasma after administration of three Capsules of Maxicura 500 mg and three Capsules of Micronized Curcumin 95% each 500 mg as single dose in fasted healthy adult human subjects. The results of the study are also compared with plasma concentration of free Curcumin by Standard Curcumin as reported in the literature [17]. **Methodology:** Comparative bioavailability of free curcumin for three Capsules of Maxicura 500 mg and three Capsules of Micronized Curcumin 95%, (500) mg was evaluated in an open label, non-randomized, two-treatment, two-period, two-group crossover study after single oral dose administration in 14 fasted healthy adult humans. The free Curcumin was determined along with pharmacokinetic parameters such as C_{max}, AUC_{0-t}, T_{1/2}, K_e, T_{max}, %AUC extra, n points, K_e first and K_e last. Linear & Semi log graphs were plotted with the help of SASR®. In addition, the total Curcuminoids (Comprising Curcumin, Bis- Demethoxy curcumin, Demethoxy curcumin & Tetra hydrocurcumin) after reaction with mixture of glucuronidas3 + sulphatase enzyme was estimated in plasma using validated LC-MS-MS method. **Results:** Data from the study reveals that the maximum measured plasma concentration of free Curcumin was 195.196 ng/mL for Maxicura and 81.270 ng/mL for Micronized Curcumin 95%. The times where maximum plasma concentration of free Curcumin achieved for the Maxicura and Micronized Curcumin 95%, were 3.129 hours and 4.750 hours respectively. **Conclusion:** Maxicura composition was 3.11 fold more bioavailable, in terms of free Curcumin level, as compared to Micronized Curcumin 95%. As it is known from the literature that, micronization enhances the bioavailability by 9 folds, one can conclude that Maxicura was 66.47(3.11/0.4 x 0.95 x 9) times more bioavailable in terms of total Curcuminoids compared to Standard Curcumin extract powder 95% and based on the literature study, provides 172 times more bioactive free Curcumin when compared to Standard Curcumin 95%.

Trial registration: CTRI/2021/12/038530 [Registered on: 09/12/2021]

Keywords: Free curcumin; Bioavailability; Maxicura; 95% Curcuminoids; Human Subjects; Standard curcumin Extract powder 95%.

Introduction

Maxicura, a curcumin composition made by using proprietary LIMAN technology which involves encapsulation with plant derived lipid matrix, with 40% curcuminoids concentration, is compared with Micronized Curcumin extract 95% for oral absorption and bioavailability. The study was conducted on 14 human subjects under fasting condition with 3 capsules of 500mg of Maxicura and 3 x500mg of Curcumin extract 95%-Micronized. The free Curcuminoids levels as well as their metabolites are measured in blood plasma with and without glucuronidase/sulfatase hydrolysis. Upon dose correction, the study shows a curcuminoids relative bioavailability of 678.32% for Maxicura as compared to Micronized Curcumin. Free Curcumin in plasma obtained from Maxicura supplementation is found to be 172 times more than that of Standard Curcumin as reported in the literature [17]. Curcumin, yellow colored pigment present in turmeric, is proven to be beneficial in wide range of therapeutic areas. Curcumin is found to be effective in many health benefits including anti-inflammatory [1,6] and antioxidant effects, cancer protective properties (chemoprevention) [3-5] anti-bacterial, anti-viral and anti-fungal properties [1,2], liver [4] and kidney protection [7], cognitive properties [8], and having antidepressant [9], antidiabetic [10] and immune modulating properties [11]. While it has demonstrated potent health benefits in in-Vitro tests, one needs to administer much larger dose, such as 2-8gms/day to achieve any measurable health benefits upon oral administration. Main reason for the requirement of such large dose is its poor bioavailability, instability in gastrointestinal tract and quick, extensive metabolism in the intestine as well as liver to form inactive metabolites.

There are number of research papers which suggest that the free or unmetabolized form of Curcumin is much more effective than the conjugated glucuronide or sulphate metabolite. The free form of Curcumin is found to be biologically active molecule, whereas in the conjugated forms or metabolites have little or no biological activity [21, 22].

Maxicura is a 40% Curcumin composition made with natural excipients. In the current study, free Curcumin content is measured along with Curcumin metabolites in the plasma with and without use of glucuronidase/sulphatase enzymes. The plasma concentrations of Maxicura composition is compared with reference Micronized Curcumin, which is micronized by passing through 80 mesh. Previously, Maxicura has been subjected to pharmacokinetic evaluation in Wistar rats in comparison with Standard Curcumin 95%. This study revealed Tmax for Maxicura

was 1h with a highest concentration of 17.85 ng/mL and AUC of 623.8 ng.hr/L; similarly the 95% Curcuminoids estimation revealed that the Tmax was at 1h with Cmax of 4.18 and lesser AUC of 208.8 ng.hr/L. The % relative bioavailability of free Curcumin of Maxicura was 298.75 % which that of reference micronized curcumin 95%. In addition, Maxicura was also evaluated for the single dose oral toxicity study in rats and mice after oral administration. There was no abnormality and gross lesions were present in any of the mice and rats with highest dose of 2000 mg/kg. NOAEL of Maxicura was also deciphered at 440 mg/kg and 220 mg/kgbw. in rats and rabbits repeated dose 28 days toxicity study respectively.

Currently there are a just few compositions of Curcumin which do not use the glucuronidase/sulphatase in their bioanalytical methodology and show significant levels of free Curcumin in the plasma. Some of these are Curcumin Active™ [12] (utilizing Longivida® form of curcumin) and Curcumin Ultra (using CurQfen® form of curcumin) [13,14].

Methods

Subjects

The present clinical study was conducted in healthy, adult, human subjects of age 18 to 45 years (Male: 34.43 ± 5.83 Years; Female 29.57 ± 6.24 years) recruited from the pool of healthy volunteers. A total of 14 healthy subjects were enrolled. Subjects from the pool of healthy volunteers who were screened within 21 days prior to the first dosing day has been considered as potential participants in the study. Volunteers were only admitted to the study after having signed the informed consent form. There was no subject drop out observed during the study duration. The protocol was approved by ANVESHAN Independent Ethics Committee, B-8, Simandhar Residency, Near Gulab Tower, Behind Utopia School, Thaltej, Ahmedabad-380054. Gujarat, India. The study protocol was approved bearing IEC no. ARL/CSP/2021/001-00 [IEC approved on: 29/11/2021]. Subjects were acquired at clinical site Macleods Pharmaceuticals Ltd., Bioequivalence Department, R&D IV, 5th Floor, Empire Doctor House, Opp. Kargil Petrol Pump, Science city road, Sola, Ahmedabad 380 060, India.

Inclusion Criteria

1. Healthy volunteers within the age range of 18 to 45 years (both inclusive).
2. Presently non-tobacco users (smokers and chewers).
3. Willingness to provide written informed consent to participate in the study.
4. Body-mass index (BMI) between 18.50 kg/m^2 and 29.99 kg/m^2 (both inclusive) with body weight not less than 50 kg (for males) and with body weight not less than 45 kg (for females).

- Absence of significant disease or clinically significant laboratory values or laboratory evaluation, medical history or physical examination during the screening.
- Have a normal 12-lead ECG or one with abnormality considered to be clinically insignificant.
- Have a normal chest X-ray PA view or one with abnormality considered to be clinically insignificant.
- Willing to take turmeric free food for the entire study duration.
- Comprehension of the nature and purpose of the study and compliance with the requirement of the distributed ICF.
- Volunteer is regularly menstruating / Volunteer is in postmenopausal phase for at least 1 year / is surgically sterile (for females).
- Volunteer of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s) such as condoms, foams, jellies, diaphragm, and intrauterine device (IUD) or abstinence etc. except hormonal contraceptives (for females).
- Consumption of grapefruit or grapefruit containing products or any cruciferous vegetables (e.g. broccoli, brussels sprouts, etc.) or char-broiled meat prior 7 days of investigational product administration.
- Use of any recreational drug or a history of drug addiction.
- Participation in any clinical trial within the past 90 days.
- History of difficulty with donating blood or difficulty in accessibility of veins in left or right arm.
- Donation of blood (one unit or 350 mL) within 90 days prior to receiving the first dose of study medication.
- Consumption of any other prescription drug or over the counter (OTC) drugs (including vitamins and medicinal products from natural origin) within two weeks prior to receiving the first dose of study medication or repeated use of drugs within the last four weeks and throughout subject's participation in the study.
- An unusual diet for whatever reason e.g. low sodium diet, for two weeks prior to receiving any medication and throughout subject's participation in the study.
- Recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 48 hours prior to the study.
- Use of oral contraceptive in last 90 days (for females).
- Pregnant / lactating volunteers (for females).

Exclusion Criteria

- Personal history of allergy or hypersensitivity to Curcumin or to any components of the formulation or allied drugs or excipients.
- Any major illness in the past 90 days or any clinically significant ongoing chronic medical illness e.g. Congestive Cardiac Failure, Hepatitis, Hypotensive episodes, Hyperglycemia etc.
- Presence of any clinically significant abnormal laboratory values during screening e.g. significant abnormality of liver function test, renal function test etc.
- Severe cardiac, renal or liver impairment, gastro-intestinal disease or other conditions, any other organ or system impairment.
- History of seizures, epilepsy or any kind of Neurological disorders.
- History of hypercalcemia or vitamin D toxicity.
- Past history of Anaphylaxis or angioedema.
- Presence of disease markers of HIV or Hepatitis B or Hepatitis C virus.
- History of chronic consumption of any kind of alcoholic beverages for more than 2 years or having consumed alcohol within 48 hours prior to check-in.
- Consumption of products containing xanthine derivatives (chocolates, tea, coffee or cola drinks) or tobacco products within 48 hours prior to check-in.

Study Material

Maxicura 500 mg Capsules (Test) and Micronized Curcumin 95%, 500 mg Capsules (Reference) were obtained from India Glycols Ltd, NOIDA, India. This study includes analytical method validation not only for total Curcuminoids but also for metabolites such as glucuronides/sulphates (details are not included). Since Standard Curcumin 95% do not produce detectable free Curcumin plasma concentrations even at larger doses, it was decided to use Micronized Curcumin 95%, which, as per published research, has 9 -10 times higher bioavailability and can be easily quantified in plasma with minimum error [18].

Study Design

An open label, non-randomized, two-treatment, two-period, single dose, two-group crossover study on healthy, adult, human subjects under fasting condition. Duration of the study is 21 days including 14 days washout period. It is an open labelled study because there was no possibility to blind the appearance of the products. The analysts concerned, however, were informed regarding sequence of administration of test and reference product to the individual subjects. The order of receiving treatment was non-randomized, i.e., in period I, 3 male & 4 female subjects has

been administered Maxicura while 3 female & 4 male subjects has been administered Micronized Curcumin. In period II, crossover has been done. Subjects served as their own control, the study being of crossover design. The blood sampling time scheduled is intended to cover the expected Tmax of Total Curcuminoids of 1.00 hour as shown in the previous study. The last sample was collected at 24.00 hours post-dose, is more than 3 times the reported half-life of Total Curcuminoids (approximately 4.00 to 6.00 hrs), as per previous study data and covers at least 80% of the extrapolated AUC [15].

Study Procedure

An oral dose of three capsules of Maxicura or Micronized Curcumin 95%, 500 mg were administered at 0.00 hour during each period. Maxicura or Micronized Curcumin 95%, 500 mg administered with 240 mL (about 8 oz) of drinking water at room temperature under the supervision of the medical officer where start time of the dosing was recorded in investigational product administration forms. The dosing interval between two consecutive subjects was 3 minutes.

Dosing has been done as per below;

In period I, 3 male & 4 female subjects had been administered three capsules (3 X 500 mg) of Maxicura 500 mg Capsule and 4 male & 3 female subjects had been administered three capsules (3 X 500 mg) of Micronized Curcumin 95%, 500 mg Capsule.

In period II, crossover was done after 14 days wash out period. 4 male & 3 female subjects had been administered three capsules (3 X 500 mg) of Maxicura 500 mg Capsule and 3 male & 4 female subjects had been administered three capsules (3 X 500 mg) of Micronized Curcumin 95% 500 mg Capsule.

Bioanalytical Method

Samples were analysed using validated LC-MS-MS analytical method. During analysis all three curcuminoids, viz. Curcumin, Demethoxycurcumin and Bisdemthoxycurcumin were measured along with their metabolites, including Tetrahydrocurcumin, Glucuronides and Sulphates, with and without glucuronidase/sulphatase enzymes. The results of analysis are presented to cover Free Curcumin as well as Free Curcuminoids.

Meal Plan

After check-in, subjects has received standardized meal was provided approximately at -36.00 (i.e. dinner) on Day -2, -24.00, -20.00, -16.00 and -12.00 hours (i.e. breakfast, lunch, snacks and dinner) on Day -1. A standard meal (comprising of 2600 - 3000 Kcal) was provided approximately at 4.00, 8.00 and 12.00 hours post-dose on dosing day (day 1) (i.e. lunch, snacks and dinner),

standard meal (2600-3000 Kcal) was provided approximately at 24.00, 28.00 and 32.00 hours post dose on day 2 (i.e. breakfast, lunch and snacks) during each period.

Blood Sampling Schedule:

Blood samples (each of 5 mL) were collected in 5 mL blood collection tube containing K3EDTA as anticoagulant during each period. The venous blood samples had been withdrawn at -06.00 hours, pre-dose and at 00.25, 00.50, 00.75, 01.00, 01.33, 01.67, 02.00, 02.50, 03.00, 03.50, 04.00, 06.00, 08.00, 12.00, 16.00 and 24.00 hours post-dose.

Statistical Analysis

Summary statistics, ANOVA, Intra-subject variability, 90% Confidence interval and Power was calculated using SAS® Linear software. Descriptive statistics has been provided for all pharmacokinetic parameters for Total Curcuminoids tests and reference compositions with and without baseline corrections. Statistical analysis has also been done separately for male and female subjects. Since this is a proof-of -concept design, the outcomes are not evaluated for statistical significance.

Results

Primary pharmacokinetic parameters of free curcuminoids were evaluated for all the samples. For Curcumin, mean of AUCt Micronized Curcumin 95% was 863.27 (ng.h/ml) whereas for MAXICUMA 2686.16 (ng.h/ml) was observed. % Relative bioavailability of curcumin in case of Maxicura was found to be 311.16%.

For BDMC, mean of AUCt Micronized Curcumin 95% for was 29.33 (ng.h/ml) whereas for MAXICUMA 83.78 (ng.h/ml) was observed. % Relative bioavailability of BDMC in case of Maxicura was found to be 285.61%.

For DMC, mean of AUCt for Micronized Curcumin 95% was 270.93 (ng.h/ml) whereas for MAXICUMA 846.91 (ng.h/ml) was observed. % Relative bioavailability of DMC in case of Maxicura was found to be 312.58%.

For THC, mean of AUCt for Micronized Curcumin 95% was 367.41 (ng.h/ml) whereas for MAXICUMA 1707.57 (ng.h/ml) was observed. % Relative bioavailability of THC in case of Maxicura was found to be 464.76%.

Since Maxicura is at 40% concentration as compared to Micronized Curcumin which is at 95% concentration, a correction factor of 2.375 has been applied to determine the exact fold increase in the bioavailability. With this correction, Maxicura shows 678.32% increase in relative bioavailability as compared to Micronized Curcumin.

For COG, mean of AUCt for Micronized Curcumin 95% was 224.84 (ng.h/ml) whereas for MAXICUMA 699.56 (ng.h/ml) was observed. % Relative bioavailability of THC in case of Maxicura was found to be 311.13%.

For COS, mean of AUCt for Micronized Curcumin 95% was 802.40 (ng.h/ml) whereas for MAXICUMA 7668.75 (ng.h/ml) was observed. % Relative bioavailability of THC in case of Maxicura was found to be 955.72%.

Discussion

Curcumin, the single most active principle of Turmeric has gained popularity in recent times for its health benefits such as anti-inflammatory effect in bone health, neuroprotective effects, immunomodulatory effects, anticancer effects and many more. While Curcumin effects are exemplary in *in-Vitro* and cell-line studies at low concentrations, its health benefits in *in-Vivo* animal studies and human clinical trials cannot be demonstrated even at large doses. Main reasons for the lack of efficacy in *in-Vivo* or human trials are a) instability of Curcumin in various physiological pHs in the intestine leading to its significant destruction in the gastrointestinal tract, b) poor absorption due to insolubility of Curcumin in gastro-intestinal fluids and c) extensive metabolism of Curcumin in gastrointestinal tract as well as in the liver to inactive metabolites. Due to these reasons, about 50% of curcuminoids are excreted in feces unabsorbed, less than 1% of the absorbed Curcuminoids can be found in the blood plasma in unmetabolized form even with large doses [25] and 10-15% of the Curcuminoids are degraded in the gastrointestinal tract before being absorbed. Unless all three above mentioned issues are addressed, one cannot realize high therapeutic potential of Curcumin in a clinical trial.

Numerous attempts have been reported in the literature that address one or more of the above listed issues [24]. Micronization, microencapsulation with hydrophilic films, use of high amounts of surfactants, molecular dispersion, micellization, complexation, entrapment in fibers, entrapment in micro tube structures, solid-lipid nanoparticles, liposomal technology, use of piperine to limit metabolism etc. have been tried to enhance the efficacy of Curcumin, but with limited success. Reason being, none of these technologies address all the three issues listed above. Most Curcumin compositions developed in recent times address poor absorption and very few on protecting Curcumin from harsh physiological conditions and microsomal enzymes. Net result

being low concentration of unmetabolized or free curcumin in plasma/serum even with large doses. Only Longvida, with 80% phospholipid composition and CurQfen, a complex with fenugreek soluble fibers, have been able to show reasonably higher concentration of unmetabolized or free Curcumin in plasma/serum during human bioavailability studies [13,14]. However, to achieve best therapeutic benefits in chronic inflammation, unmetabolized or free Curcumin should be even higher in concentration and should remain in plasma/serum for longer time, in other words, with a prolonged half-life. Longer plasma half-life will not only help in ameliorating chronic inflammation but also in developing One-A-Day tablet/capsule regimen, which is most desirable and consumer compliant.

Maxicura, a unique Curcumin composition made with LIMAN (Lipid Matrix Nano encapsulation) technology [26], addresses all the issues of poor Curcumin efficacy. It provides high stability to curcumin at all the physiological pHs, has excellent solubility in water and most important, prevents rapid metabolism of Curcumin, not only in gastrointestinal tract, but also in the liver. Its plasma half-life is significantly longer than most Curcumin compositions reported in the literature.

In this study, we have chosen Micronized Curcumin rather than Standard Curcumin for comparison of bioavailability due to the fact that the later produces undetectable amounts of unmetabolized Curcumin in the plasma even with large dose. The Cmax value 0.074ng/ml and AUC 0.072ng-h/ml for Standard Curcumin are considered for comparison purpose from a past published study [17]. It has been established that Micronized Curcumin delivers 9-10 fold higher plasma concentration of Curcumin as compared to Standard Curcumin [18]. In this study, the plasma concentrations of Curcumin, Demethoxycurcumin, Bisdemethoxycurcumin and their metabolites are measured by LCMS/MS method with and without glucuronidase/sulfatase enzyme treatments.

Tables 1 to 12 show the plasma concentrations of Curcumin, Demthoxycurcumin, Bisdemethoxycurcumn, Tetrahydrocurcumin, Curcumin glucuronides and Curcumin sulfates for Micronized Curcumin and Maxicura. Table 13 shows the concentration of Free Curcumin and Free Curcuminoids at different time intervals as compared to standard curcumin data available in the prior literature.

Table 1: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: Micronized Curcumin- 95%.

Pharmacokinetic Parameters	95% Curcuminoids Formulation					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Cmax (ng/mL)	14	81.27	88.10	46.55	57.28	19.25 - 161.12
AUCt (ng.h/mL)	14	863.27	853.31	764.46	88.55	17.24 - 2112.03
AUCinf (ng.h/mL)	7	3384.69	2658.34	2443.66	72.20	410.12 - 6863.62
Tmax (h)	14	4.75	4.50	3.68	77.52	0.75 - 12.00
Thalf (h)	7	29.89	32.06	22.99	76.91	2.94 - 68.65
Ke (h ⁻¹)	7	0.06	0.02	0.08	128.98	0.01 - 0.24
Res_area (%)	7	46.52	55.45	29.29	62.97	1.54 - 80.68
% AUC extrea	7	46.52	55.45	29.29	62.97	1.54 - 80.68
Ke_First (h)	7	7.43	8.00	2.99	40.27	2.00-12.00
Ke_Last (h)	7	24.00	24.00	0.00	0.00	24.00-24.00

Table 2: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: Maxicura.

Pharmacokinetic Parameters	Maxicura Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Cmax (ng/mL)	14	195.20	195.82	123.64	63.34	36.22 - 384.13
AUCt (ng.h/mL)	14	2686.16	2594.81	2199.67	81.89	147.67 - 5290.47
AUCinf (ng.h/mL)	11	8316.50	1751.65	10258.98	123.36	154.50 - 31252.36
Tmax (h)	14	3.13	2.00	2.63	83.94	0.25 - 8.00
Thalf (h)	11	24.02	15.94	26.63	110.89	1.69 - 86.90
Ke (h ⁻¹)	11	0.11	0.04	0.13	122.40	0.01 - 0.41
Res_area (%)	11	41.60	42.15	29.08	69.90	4.42 - 85.35
% AUC extrea	11	41.60	42.15	29.08	69.90	4.41 - 85.35
Ke_First (h)	11	7.21	6.00	3.71	51.46	1.33-12.00
Ke_Last (h)	11	20.36	24.00	5.20	25.55	12.00-24.00

Table 3: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: BDMC- 95% Curcuminoids.

Pharmacokinetic Parameters	95% Curcuminoids Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Cmax (ng/mL)	14	2.56	3.02	1.21	47.46	0.74 - 3.98
AUCt (ng.h/mL)	14	29.33	32.87	20.43	69.67	1.00 - 54.89
AUCinf (ng.h/mL)	9	91.84	74.18	78.50	85.48	6.19 - 274.80
Tmax (h)	14	6.15	5.00	6.16	100.16	0.75 - 24.00
Thalf (h)	9	22.57	14.16	20.52	90.92	7.18 - 70.88
Ke (h ⁻¹)	9	0.05	0.05	0.03	60.06	0.01 - 0.10

Pharmacokinetic Parameters	95% Curcuminoids Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Res_area (%)	9	45.12	50.44	23.64	52.39	16.07 - 82.32
% AUC extrea	12	45.12	50.44	23.64	52.39	16.07 - 82.32
Ke_First (h)	9	4.93	6.00	2.88	58.45	1.00-8.00
Ke_Last (h)	9	23.11	24.00	2.67	11.54	16.00-24.00

Table 4: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: BDMC- Maxicuma.

Pharmacokinetic Parameters	Maxicuma Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Cmax (ng/mL)	14	7.48	5.24	5.39	72.06	2.31 - 19.86
AUCt (ng.h/mL)	14	83.78	85.41	50.34	60.08	26.91 - 203.99
AUCinf (ng.h/mL)	13	182.50	184.78	103.82	56.89	32.72 - 357.51
Tmax (h)	14	6.60	6.00	4.88	73.97	1.33 - 16.00
Thalf (h)	13	32.43	21.23	32.92	101.51	4.78 - 113.37
Ke (h)	13	0.05	0.03	0.05	87.96	0.01 - 0.14
Res_area (%)	13	46.05	43.72	28.83	62.62	10.35 - 89.42
% AUC extrea	13	45.80	43.72	28.69	62.65	10.35 -89.42
Ke_First (h)	13	8.15	8.00	3.51	43.05	2.00-12.00
Ke_Last (h)	13	23.38	24.00	2.22	9.49	16.00-24.00

Table 5: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: DMC- 95% Curcuminoids.

Pharmacokinetic Parameters	95% Curcuminoids Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Cmax (ng/mL)	14	32.56	33.88	20.26	62.21	2.65 - 64.91
AUCt (ng.h/mL)	14	270.93	277.18	228.20	84.23	4.06 - 619.48
AUCinf (ng.h/mL)	6	1177.76	796.29	1169.23	99.28	375.04 - 3532.79
Tmax (h)	14	6.95	6.00	6.70	96.42	0.75 - 24.00
Thalf (h)	6	32.25	18.20	35.56	110.27	8.55 - 103.32
Ke (h)	6	0.04	0.04	0.03	64.41	0.01 - 0.08
Res_area (%)	6	44.74	39.52	20.56	45.95	22.49 - 82.46
% AUC extrea	6	44.73	39.18	20.56	45.95	22.49 -82.46
Ke_First (h)	6	4.13	4.00	2.91	70.57	0.75-8.00
Ke_Last (h)	6	24.00	24.00	0.00	0.00	24.00-24.00

Table 6: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: DMC- Maxicuma.

Pharmacokinetic Parameters	Maxicura Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
C _{max} (ng/mL)	14	103.93	91.71	73.22	70.45	14.81 - 233.17
AUC _t (ng.h/mL)	14	846.91	688.61	654.39	77.27	55.31 - 1797.19
AUC _{inf} (ng.h/mL)	12	1420.59	1497.72	1036.06	72.93	179.56 - 3297.77
T _{max} (h)	14	3.61	2.29	2.63	72.76	0.75 - 8.00
T _{half} (h)	12	10.78	10.97	7.27	67.45	1.59 - 30.19
K _e (h ⁻¹)	12	0.11	0.06	0.11	102.91	0.02 - 0.44
Res_area (%)	12	26.10	25.37	13.13	50.32	0.44 - 51.87
% AUC extrea	12	26.10	25.35	13.13	50.31	0.44 - 51.87
K _e _First (h)	12	4.88	6.00	3.57	73.13	0.75-12.00
K _e _Last (h)	12	21.33	24.00	4.92	23.08	12.00-24.00

Table 7: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: THC- 95% Curcuminoids.

Pharmacokinetic Parameters	95% Curcuminoids Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
C _{max} (ng/mL)	14	35.26	23.38	36.90	104.67	4.33 - 115.50
AUC _t (ng.h/mL)	14	367.41	321.95	323.18	87.96	12.10 - 1096.91
AUC _{inf} (ng.h/mL)	3	761.37	720.49	649.40	85.29	133.37 - 1430.24
T _{max} (h)	14	15.71	16.00	2.92	18.58	12.00 - 24.00
T _{half} (h)	3	16.16	8.72	18.72	115.85	2.30 - 37.45
K _e (h ⁻¹)	3	0.13	0.08	0.15	111.75	0.02 - 0.30
Res_area (%)	3	32.78	28.76	33.62	102.56	1.35 - 68.22
% AUC extrea	3	32.78	28.76	33.62	102.56	1.35 - 68.22
K _e _First (h)	3	12.00	12.00	0.00	0.00	12.00-12.00
K _e _Last (h)	3	24.00	24.00	0.00	0.00	24.00-24.00

Table 8: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: THC- Maxicura.

Pharmacokinetic Parameters	Maxicura Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
C _{max} (ng/mL)	14	133.93	141.03	91.93	68.64	25.89 - 302.62
AUC _t (ng.h/mL)	14	1707.57	1585.46	1320.79	77.35	318.22 - 4794.17
AUC _{inf} (ng.h/mL)	7	2213.33	1958.01	1856.03	83.86	596.21 - 5737.18
T _{max} (h)	14	10.29	14.00	7.84	76.17	1.67 - 24.00
T _{half} (h)	7	15.82	12.80	9.93	62.80	6.36 - 36.01
K _e (h ⁻¹)	7	0.06	0.05	0.03	53.24	0.02 - 0.11
Res_area (%)	7	35.08	35.80	17.47	49.79	11.85 - 67.84
% AUC extrea	7	35.08	35.80	17.47	49.79	11.85 - 67.84

Pharmacokinetic Parameters	Maxicuma Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Ke_First (h)	7	7.82	12.00	5.23	66.86	1.67-12.00
Ke_Last (h)	7	24.00	24.00	0.00	0.00	24.00-24.00

Table 9: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: COG- 95% Curcuminoids.

Pharmacokinetic Parameters	95% Curcuminoids Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Cmax (ng/mL)	14	31.10	32.30	5.17	16.62	13.65 - 35.48
AUCt (ng.h/mL)	14	224.84	236.10	53.75	23.91	126.44 - 287.58
AUCinf (ng.h/mL)	14	1612.95	1411.48	1509.40	93.58	240.70 - 6052.65
Tmax (h)	14	1.73	1.21	1.45	84.26	0.25 - 6.00
Thalf (h)	14	92.21	76.13	104.19	112.99	7.85 - 404.55
Ke (h ⁻¹)	14	0.03	0.01	0.03	119.04	0.01 - 0.09
Res_area (%)	14	73.89	83.27	20.71	28.03	37.59 - 95.38
% AUC extrea	14	73.89	83.27	20.71	28.03	37.59 - 95.38
Ke_First (h)	14	3.71	2.75	2.97	80.10	1.33-12.00
Ke_Last (h)	14	20.29	24.00	5.54	27.30	8.00-24.00

Table 10: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: COG- Maxicuma.

Pharmacokinetic Parameters	Maxicuma Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Cmax (ng/mL)	14	93.816	90.29	35.7851	38.14	37.17 - 175.24
AUCt (ng.h/mL)	14	699.55525	708.8299	121.074156	17.31	445.73 - 864.44
AUCinf (ng.h/mL)	14	3255.63593	3148.1601	1208.234571	37.11	1575.85 - 5394.11
Tmax (h)	14	1.546	1.33	0.7708	49.87	0.75 - 3.00
Thalf (h)	14	72.78818	68.0057	36.622078	50.31	19.80 - 135.43
Ke (h ⁻¹)	14	0.01298	0.0102	0.008510	65.58	0.01 - 0.04
Res_area (%)	14	74.955	79.54	12.1493	16.21	47.25 - 88.03
% AUC extrea	14	74.95479	79.5424	12.1493	16.21	47.25 - 88.03
Ke_First (h)	14	8.45	10.0000	4.0530	47.96	1.67-12.00
Ke_Last (h)	14	23.43	24.0000	2.1381	9.13	16.00-24.00

Table 11: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: COS- 95% Curcuminoids.

Pharmacokinetic Parameters	95% Curcuminoids Composition					
	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Cmax (ng/mL)	14	73.20	54.31	56.11	76.65	0.00 - 171.04

	95% Curcuminoids Composition					
Pharmacokinetic Parameters	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
AUCt (ng.h/mL)	13	802.40	79.26	951.72	118.61	10.65 - 2423.62
AUCinf (ng.h/mL)	6	10694.82	1843.33	22348.09	208.96	63.63 - 56258.77
Tmax (h)	14	5.59	6.00	4.49	80.35	0.25 - 16.00
Thalf (h)	6	86.00	8.65	192.71	224.08	3.52 - 479.33
Ke (h)	6	0.09	0.08	0.07	71.43	0.01 - 0.20
Res_area (%)	6	33.47	23.73	32.00	95.62	7.53 - 96.95
% AUC extrea	6	33.47	23.73	32.00	95.62	7.53 - 96.95
Ke_First (h)	6	6.83	7.00	3.24	47.37	3.50-12.00
Ke_Last (h)	6	22.00	24.00	4.90	22.27	12.00-24.00

Table 12: Pharmacokinetic Analysis - Primary & Secondary Parameter of Free Curcuminoids: COS- Maxicura.

	Maxicura Composition					
Pharmacokinetic Parameters	N	Mean	Median	S.D.	C.V.	(Minimum - Maximum)
Cmax (ng/mL)	14	656.07	651.41	354.87	54.09	269.44 - 1323.63
AUCt (ng.h/mL)	14	7668.75	6278.80	7215.61	94.09	391.61 - 20203.03
AUCinf (ng.h/mL)	6	19746.06	16434.46	18589.93	94.14	716.33 - 48410.21
Tmax (h)	14	8.12	6.00	4.76	58.63	3.50 - 16.00
Thalf (h)	6	10.74	8.91	10.29	95.79	0.71 - 27.80
Ke (h)	6	0.30	0.08	0.40	133.26	0.02 - 0.98
Res_area (%)	6	25.04	22.57	22.41	89.49	0.97 - 59.82
% AUC extrea	6	25.04	22.57	22.41	89.49	0.97 - 59.82
Ke_First (h)	6	7.69	7.00	3.65	47.41	4.00-12.00
Ke_Last (h)	6	18.67	24.00	8.26	44.25	8.00-24.00

Table 13: Total Free Curcumin in Maxicura at different Time interval (ng.h/mL).

Input	subjects	1	2h	4h	6h	8h	12h	16h	24h
Free Curcumin	14	130	110	110	120	140	110	120	110
Total free curcumin	14	214.5	206.5	173.5	192.5	219.75	203.5	217.5	183

Table 14: Comparison of % Free or Unmetabolized Curcumin/ Total Curcumin, including metabolites.

Parameter	Maxicura-40%	Curcumin 95%-Standard (Data taken from literature)
AUC data for Maxicura –Free curcumin(ng.h/ml)	2686.16	0.072
AUC data for Total free Curcumin (ng.h/ml) (Curcumin+ THC+ COG+COS)	12762.03	24.774
Ratio of free to total curcumin	21.04	0.29
Free Curcumin Fold	72.55	
With the Dose correction for Maxicura (40%) and Curcumin (95%) , 95/40 =2.375	72.55 x 2.375 172.3 Fold	

This study emphasizes the importance of unmetabolized Curcumin (Free form of Curcumin) in plasma. There is ample evidence in the literature that reiterates the importance of unmetabolized Curcumin as most potent therapeutic agent as compared to its metabolites [21, 22]. Moreover, the metabolites such as glucuronides and sulphates are water soluble and are readily eliminated from the plasma within short duration. Hence, for any therapeutic benefit, it is imperative consider the Free Curcumin concentration in plasma. While Tetrahydro curcumin, one of the major metabolites of Curcumin, is reported to have potent anti-inflammatory properties, has little contribution to the health benefits of Curcumin due to the fact that it too undergoes further metabolism to form glucuronides and sulphates and get eliminated from the plasma in a short duration. Bisdemethoxycurcumin appears to be more stable, more potent and less metabolized, but it is occurs in low (3-5%) concentration among other curcuminoids.

The level of total free curcuminoids in Maxicura, Micronized Curcumin and Curcumin Standard (taken from literature data) and free Curcumin in Maxicura and Micronized Curcumin and

Standard Curcumin is presented in Fig 1 and 2 respectively. In Table No 13, comparison is made between plasma concentration of Free Curcumin and Total Free Curcumin (includes Demethoxycurcumin and Bisdemethoxycurcumin, Tetrahydrocurcumin). Table 13 entails concentrations of unmetabolized curcumin and curcuminoids at different time intervals. In Tables 1 to 12, the data represents measurement of curcuminoids in the plasma with and without glucuronidase/sulphatase enzyme. Further, the values of demethoxy curcumin, bisdemethoxy curcumin and tetrahydracurcumin were measured in blood plasma in their free form without the use of glucuronidase/sulphatase enzymes. These are considered for total free curcuminoid level calculation in the plasma at different time intervals. Though as mentioned above the curcumin metabolites, curcumin glucuronide and curcumin sulphate are analysed, but were not considered for the calculation of free Curcumin level and bioavailability. Thus, the current study provides concentrations of free Curcuminoid levels, rather than the concentrations of Curcuminoids plus metabolites, emphasizing the fact that it is free or unmetabolized Curcumin that renders desired therapeutic benefits of Curcumin.




Figure 1: Total Free Curcumin level in Plasma for Maxicura Verses Standard curcumin 95% (Data taken from literature).




Figure 2: Free Curcumin level in Maxicura Verses Standard curcumin 95% (Data taken from literature).




Figure 3: Free Curcumin Level in Maxicura with and without dose correction.

Tables 13 and 14 explain the difference in the plasma concentrations of Free or unmetabolized Curcumin between Maxicura and Standard Curcumin 95% whose data is available in the prior at published literature. Maxicura, at 40% Curcuminoid content has about 172 times higher amounts of free or unmetabolized Curcumin as compared to Standard Curcumin 95% (taken from literature data). With such high concentrations of plasma Free Curcumin, Maxicura surpasses many other Curcumin compositions, such as Longvida or CurQfen, in delivering therapeutically potent form of Curcumin. At 40% Curcuminoid content, Maxicura stands out as a composition providing highest strength of curcuminoids along with high physiological stability, high water solubility and highest concentration of plasma free Curcumin, that too in a One-a-Day tablet/capsule regimen. Superior water solubility of Maxicura also makes it suitable for applications such as Shots and Ready-to-Drink beverages.

Conclusion

Maxicura, with 40% Curcuminoids, delivers significantly high plasma concentrations of unmetabolized or free Curcumin as compared to Micronized Curcumin 95%. When compared with Standard Curcumin 95% (as reported in the literature), Maxicura provides 172 times more free or unmetabolized plasma concentrations with a half-life well beyond 24 hours, making it suitable for one-a-day dosage regimen. Being water soluble, Maxicura can easily be incorporated in to shots and ready-to-drink beverages.

Ethics approval and consent to participate

The study was conducted in accordance to all pertinent

requirements of international, national bio ethics guideline and ICH ‘Guideline for Good Clinical Practice’, and in accordance with New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940, AYUSH and CDSCO requirement and Declaration of Helsinki (2013).

The study has been submitted to the ANVESHAN Independent Ethics Committee, Ahmedabad with protocol no. ARL/CSP/2021/001-00 approved on date of 29th November 2021. This trial was also registered with clinical trial registration of India (CTRI) with registration number CTRI/2021/12/038530 [Registered on: 09/12/2021].

Consent for Publication

As no personal data are included in the present manuscript, this section is not applicable.

Availability of data and materials

As per our SOP, all the studies related data are archived for 9 years from the data of archival of the study at research facility Accuprec Research Labs Pvt. Ltd. Ahmedabad, India.

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

The present study was funded by the Sponsor M/S India Glycols Limited (HQ) having head quarter at, 2B, Sector-126, Noida, Gautam Budh Nagar, Uttar Pradesh 201 304 and having production site at Plot No. 2, 3, 4 & 5, Pharmacy, Selaqui, Dehradun, Uttarakhand, India.

Authors' contributions

MR and RG has prepared the whole manuscripts. HP has prepared the tables, figures and appendices of the manuscript. JK has done the data analysis. AP has done the whole bio analysis for the present study. All the authors read and approved the final manuscript.

References

1. Lestari ML, Indrayanto G (2014) Curcumin. *Profiles Drug Subst Excp Relat Methodol* 39:113-204.
2. Mahady GB, Pendland SL, Yun G, Lu ZZ (2002) Turmeric (*Curcuma longa*) and curcumin inhibit the growth of *Helicobacter pylori*, a group 1 carcinogen. *Anticancer Res* 22: 4179-4181.
3. Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN (2005) Curcumin for malaria therapy. *Biochem Biophysics Res Commun* 326:472-474.
4. Vera-Ramirez L, Perez-Lopez P, Varela-Lopez A, Ramirez-Tortosa M, Battino M, et al., (2013) Curcumin and liver disease. *Biofactor*. 39:88-100.
5. Wright LE, Frye JB, Gorti B, Timmermann BN, Funk J (2013) Bioactivity of turmeric-derived Curcuminoids and related metabolites in breast cancer. *Curr Pharm Des* 19:6218-6225.
6. Aggarwal BB, Harikumar KB (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int. J Biochem Cell Biol* 41:40-59.
7. Ghosh SS, Gehr TW, Ghosh S (2014) Curcumin and Chronic Kidney Disease (CKD): Major Mode of Action through Stimulating Endogenous Intestinal Alkaline Phosphatase. *Molecules* 19: 20139-20156.
8. Sarker MR, Franks SF (2018) Efficacy of curcumin for age-associated cognitive decline: a narrative review of preclinical and clinical studies. *Geroscience* 40:73-95.
9. Ramaholimihaso T, Bouazzaoui F, Kaladjian A (2020) Curcumin in Depression: Potential Mechanisms of Action and Current Evidence—A Narrative Review. *Front Psychiatry* 11: 572533.
10. Hartogh DJ, Gabriel A, Tsani E (2020) Antidiabetic properties of curcumin I, Evidence from in vitro studies *Nutrients* 12: 118.
11. Yuandani, Jantan I, Rohani AS, Sumantri IB (2021) Immunomodulatory effects and Mechanisms of curcuma species and their Bioactive compounds : A Review. *Front Pharmacol* 12:643119.
12. Tabanelli R, Brogi S, Calderone V (2021) Improving Curcumin Bioavailability: Current Strategies and Future Perspectives. *Pharmaceutics* 13:1715.
13. Pancholi V, Smina TP, Kunnumakkara AB, Maliakel B, Krishnakumar IM (2021) Safety assessment of a highly bioavailable curcumin-galactomannoside complex (CurQfen) in healthy volunteers, with a special reference to the recent hepatotoxic reports of curcumin supplements: A 90-days prospective study. *Toxicol Rep* 8:1255-1264.
14. CurQfen curcumin may provide immune health benefits, *Nutraceutical Business Review* June 2020.
15. GENERAL GUIDELINES FOR CLINICAL EVALUATION OF AYURVEDIC INTERVENTIONS: First Edition – 2018.
16. Kumavat SD, Chaudhari YS, Borole P, Mishra P, Shenghani K, et al., (2013) Degradation studies of curcumin. *Int J Pharm Rev Res* 3:50-55.
17. Panda SK, Nirvanashetty S, Missamma M, Jackson-Michel S (2021) The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation. *Medicine (Baltimore)* 100: e26601.
18. Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, et al., (2014) The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. *Mol Nutr Food Res* 58:516-527.
19. Kumar D, Jacob D, Subash PS, Maliakkal A, Johannah NM, et al., (2016) Enhanced bioavailability and relative distribution of free (unconjugated) curcuminoids following the oral administration of a food-grade formulation with fenugreek dietary fibre: A randomised double-blind crossover study. *J Functional Food* 22: 578-587.
20. Mhaske DB, Sreedharan S, Mahadik KR (2018) Role of Piperine as an effective bioenhancer in drug absorption. *Pharm Anal Acta* 9: 1-4.
21. Pal A, Sung B, Prasad BA, Schuber PT, Prasad S, et al., (2014) Curcumin glucuronides: assessing the proliferative activity against human cell lines. *Bioorg Med Chem Lett* 22:435-439.
22. Stohs SJ, Ray SD (2019) Issues with human bioavailability determinations of bioactive curcumin. *biomed J Sci Tech Res* 12: 001-003.
23. Krishnakumar IM, Maliakel A, Gopakumar G, Kumar D, Maliakel B, et al., (2015) Improved blood-brain-barrier permeability and tissue distribution following the oral administration of a food-grade composition of curcumin with fenugreek fiber. *J Funct Foods* 14: 215-225.
24. Jamwal R (2018) Bioavailable curcumin compositions: A review of pharmacokinetic studies in healthy volunteers. *J Integr Med* 16:367-374.
25. Faça-Berthon P, Tenon M, Bouter-Banon SL, Manfré A, Maudet C, et al., (2021) Pharmacokinetics of a Single Dose of Turmeric Curcuminoids Depends on Formulation: Results of a Human Crossover Study. *J Nutr* 151:1802-1816.
26. https://www.indiaglycols.com/product_groups/phytochemicals_nutraceuticals.html.